Movatterモバイル変換

[0]ホーム
URL:

DK0835939T3 - Fusion proteins with proportions of immunoglobulin, their preparation and use - Google Patents

Fusion proteins with proportions of immunoglobulin, their preparation and use

Info

Publication number
DK0835939T3
DK0835939T3DK97120664TDK97120664TDK0835939T3DK 0835939 T3DK0835939 T3DK 0835939T3DK 97120664 TDK97120664 TDK 97120664TDK 97120664 TDK97120664 TDK 97120664TDK 0835939 T3DK0835939 T3DK 0835939T3
Authority
DK
Denmark
Prior art keywords
immunoglobulin
proportions
preparation
fusion proteins
protein
Prior art date
Application number
DK97120664T
Other languages
Danish (da)
Inventor
Gerd Dr Zettlmeissl
Leander Dr Lauffer
Patricia Dr Oquendo
Brian Dr Seed
Original Assignee
Sanofi Aventis Deutschland
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland, Gen Hospital CorpfiledCriticalSanofi Aventis Deutschland
Application grantedgrantedCritical
Publication of DK0835939T3publicationCriticalpatent/DK0835939T3/en

Links

Classifications

Landscapes

Abstract

A soluble fusion protein (I) comprising a human protein (II), or part of it, that is not of the immunoglobulin (Ig) family and different parts (III) of Ig molecules of any subclass, is new. An independent claim is also included for a method for preparing (I) by introducing a DNA that encodes it into a mammalian cell expression system, expressing (I), and purification by affinity chromatography through the Ig component. ACTIVITY : Hemostatic; Immunosuppressive; Antiallergic; Antianemic; Anticoagulant; Thrombolytic. No details of tests for these activities are given. MECHANISM OF ACTION : Protein substitution or inhibition.
DK97120664T1990-06-281991-06-22 Fusion proteins with proportions of immunoglobulin, their preparation and useDK0835939T3 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
DE40206071990-06-28
EP91110307AEP0464533B1 (en)1990-06-281991-06-22Fusionproteins with parts of immunoglobulins, their production and use

Publications (1)

Publication NumberPublication Date
DK0835939T3true DK0835939T3 (en)2006-03-13

Family

ID=6409260

Family Applications (2)

Application NumberTitlePriority DateFiling Date
DK97120664TDK0835939T3 (en)1990-06-281991-06-22 Fusion proteins with proportions of immunoglobulin, their preparation and use
DK91110307TDK0464533T3 (en)1990-06-281991-06-22 Fusion proteins with immunoglobulin moieties, their preparation and use

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
DK91110307TDK0464533T3 (en)1990-06-281991-06-22 Fusion proteins with immunoglobulin moieties, their preparation and use

Country Status (16)

CountryLink
EP (3)EP0464533B1 (en)
JP (2)JPH05247094A (en)
KR (3)KR100249572B1 (en)
AT (2)ATE169030T1 (en)
AU (1)AU655421B2 (en)
CA (1)CA2045869C (en)
CY (2)CY2151B1 (en)
DE (3)DE59109269D1 (en)
DK (2)DK0835939T3 (en)
ES (2)ES2251009T3 (en)
GR (1)GR3027567T3 (en)
IE (1)IE912256A1 (en)
LU (1)LU90592I2 (en)
NL (1)NL300009I2 (en)
PT (1)PT98113B (en)
UY (1)UY25897A1 (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NZ235148A (en)1989-09-051991-12-23Immunex CorpTumour necrosis factor receptor protein and dna sequences
US5395760A (en)*1989-09-051995-03-07Immunex CorporationDNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en)1989-09-052003-04-01Immunex CorporationFusion proteins comprising tumor necrosis factor receptor
DE10399023I2 (en)*1989-09-122006-11-23Ahp Mfg B V TFN-binding proteins
EP0533006A1 (en)*1991-09-181993-03-24F.Hoffmann-La Roche & Co. AktiengesellschaftChimaeric interleukin 5-receptor/immunoglobulin polypeptides
DE4322330A1 (en)1992-08-311994-03-03Behringwerke Ag Use of the IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases as well as fungal infections
US5643570A (en)*1992-05-191997-07-01Xoma CorporationBPI-immunoglobulin fusion proteins
US6274348B1 (en)1992-05-192001-08-14Xoma CorporationMethods for the preparation of positively charged proteins
DE4228839A1 (en)*1992-08-291994-03-03Behringwerke Ag Methods for the detection and determination of mediators
EP0760849A1 (en)*1993-04-301997-03-12Incyte Pharmaceuticals, Inc.Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
DE4407386B4 (en)*1994-03-052009-01-15Dade Behring Marburg Gmbh Method for reactivation of purified membrane proteins by freezing
ES2160708T3 (en)*1994-04-282001-11-16Dade Behring Inc CALIBRATOR FOR PROTROMBINE TIME TESTS (TP).
JPH10503371A (en)*1994-07-291998-03-31スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー New compound
DE69534265T2 (en)*1994-12-122006-05-04Beth Israel Deaconess Medical Center, Inc., Boston CHIMERIC CYTOKINS AND ITS USE
US6410008B1 (en)1994-12-122002-06-25Beth Israel Hospital AssociationChimeric IL-10 proteins and uses thereof
EP0805628B1 (en)*1995-01-172003-05-02Brigham And Women's Hospital, Inc.Receptor specific transepithelial transport of immunogens
US6485726B1 (en)1995-01-172002-11-26The Brigham And Women's Hospital, Inc.Receptor specific transepithelial transport of therapeutics
DE19538716A1 (en)*1995-10-181997-04-24Behringwerke Ag Method for quantification of activated coagulation factor VII (FVIIa)
US7427492B1 (en)1995-06-052008-09-23Human Genome Sciences, Inc.Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en)1995-06-052008-09-30Human Genome Sciences, Inc.Antibodies to human tumor necrosis factor receptor-like 2
AU6163196A (en)*1995-06-071996-12-30Smithkline Beecham CorporationMethod for obtaining receptor agonist antibodies
GB9511935D0 (en)*1995-06-131995-08-09Smithkline Beecham PlcNovel compound
DE19538715A1 (en)*1995-10-181997-04-30Behringwerke Ag Process for cleaning factor VII and activated factor VII
US6936439B2 (en)1995-11-222005-08-30Amgen Inc.OB fusion protein compositions and methods
US20030040467A1 (en)1998-06-152003-02-27Mary Ann PelleymounterIg/ob fusions and uses thereof.
US7888466B2 (en)1996-01-112011-02-15Human Genome Sciences, Inc.Human G-protein chemokine receptor HSATU68
US6635743B1 (en)1996-03-222003-10-21Human Genome Sciences, Inc.Apoptosis inducing molecule II and methods of use
US7964190B2 (en)1996-03-222011-06-21Human Genome Sciences, Inc.Methods and compositions for decreasing T-cell activity
US5866341A (en)*1996-04-031999-02-02Chugai Pharmaceutical Co., Ltd.Compositions and methods for screening drug libraries
AU731123B2 (en)1996-08-162001-03-22Human Genome Sciences, Inc.Human endokine alpha
AU7155296A (en)1996-08-301998-03-19Human Genome Sciences, Inc.Interleukin-19
DE69635088T3 (en)1996-10-252012-01-26Human Genome Sciences, Inc. NEUTROKIN alpha
ATE406176T1 (en)1996-12-062008-09-15Amgen Inc IL-1 INHIBITOR IN COMBINATION THERAPY FOR THE TREATMENT OF IL-1-MEDIATED DISEASES
US6261801B1 (en)1997-01-142001-07-17Human Genome Sceineces, Inc.Nucleic acids encoding tumor necrosis factor receptor 5
US6455040B1 (en)1997-01-142002-09-24Human Genome Sciences, Inc.Tumor necrosis factor receptor 5
US7452538B2 (en)1997-01-282008-11-18Human Genome Sciences, Inc.Death domain containing receptor 4 antibodies and methods
PT1012274E (en)1997-01-282007-08-14Craig A RosenDeath domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6433147B1 (en)1997-01-282002-08-13Human Genome Sciences, Inc.Death domain containing receptor-4
US8329179B2 (en)1997-01-282012-12-11Human Genome Sciences, Inc.Death domain containing receptor 4 antibodies and methods
US6872568B1 (en)1997-03-172005-03-29Human Genome Sciences, Inc.Death domain containing receptor 5 antibodies
EP1015477B1 (en)1997-05-302010-11-10Human Genome Sciences, Inc.32 Human secreted proteins
US6242570B1 (en)1997-07-102001-06-05Beth Israel Deaconess Medical CenterProduction and use of recombinant protein multimers with increased biological activity
WO1999002709A1 (en)*1997-07-101999-01-21Beth Israel Deaconess Medical CenterRecombinant erythropoietin / immunoglobulin fusion proteins
US6187564B1 (en)1997-07-102001-02-13Beth Israel Deaconess Medical CenterDNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en)*1997-07-102000-12-26Beth Israel Deaconess Medical CenterFusion proteins with an immunoglobulin hinge region linker
JP2002017353A (en)*1997-12-192002-01-22Japan Tobacco IncMethod for determining denaturated ldl
ES2245085T3 (en)1998-01-232005-12-16Immunex Corporation ACPL DNA AND POLYPEPTIDES
EP1982990A1 (en)1998-03-192008-10-22Human Genome Sciences, Inc.Cytokine receptor common gamma chain like
US6927044B2 (en)1998-09-252005-08-09Regeneron Pharmaceuticals, Inc.IL-1 receptor based cytokine traps
US6472179B2 (en)*1998-09-252002-10-29Regeneron Pharmaceuticals, Inc.Receptor based antagonists and methods of making and using
US7083949B2 (en)1998-09-252006-08-01Regeneron Pharmaceuticals, Inc.Receptor based antagonists and methods of making and using
US6495662B1 (en)1998-10-222002-12-17The General Hospital CorporationBioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
DK1141237T3 (en)1998-12-312006-02-13Gen Hospital Corp PTH receptor and screening assay using this
WO2000046380A2 (en)1999-02-082000-08-10Chiron CorporationFibroblast growth factor receptor-immunoglobulin fusion
CA2363779A1 (en)1999-02-262000-08-31Human Genome Sciences, Inc.Human endokine alpha and methods of use
JP3660880B2 (en)*1999-05-072005-06-15ジェネンテック・インコーポレーテッド Novel chimpanzee erythropoietin (CHEPO) polypeptide and nucleic acid encoding the same
US6362324B1 (en)1999-06-302002-03-26Millennium Pharmaceuticals, Inc.17867 a novel human aminopeptidase
US6369210B1 (en)*1999-06-302002-04-09Millennium Pharmaceuticals, Inc.22012, human carboxypeptidase
AU7734800A (en)1999-09-292001-04-30General Hospital Corporation, ThePolypeptide derivatives of parathyroid hormone (pth)
US6808902B1 (en)1999-11-122004-10-26Amgen Inc.Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6248353B1 (en)1999-12-102001-06-19Dade Behring Inc.Reconstitution of purified membrane proteins into preformed liposomes
US20030143226A1 (en)2000-03-022003-07-31Yuko KobayashiHuman monoclonal antibodies against oxidized ldl receptor and medicinal use thereof
US20010053764A1 (en)2000-05-122001-12-20Sims John E.Interleukin-1 inhibitors in the treatment of diseases
EP1283851B1 (en)2000-05-262012-03-28Immunex CorporationUse of il-4r antibodies and compositions thereof
AU2001288478B2 (en)2000-08-252006-11-02Basf Plant Science GmbhPlant polynucleotides encoding prenyl proteases
US6989247B2 (en)2000-11-282006-01-24Celltech R & D, Inc.Compositions and methods for diagnosing or treating psoriasis
EP1683865A3 (en)2001-02-022006-10-25Eli Lilly & CompanyMammalian proteins and in particular CD200
DE60236646D1 (en)2001-04-132010-07-22Human Genome Sciences Inc Anti-VEGF-2 antibodies
MXPA03010747A (en)2001-05-252004-03-02Human Genome Sciences IncAntibodies that immunospecifically bind to trail receptors.
US7348003B2 (en)2001-05-252008-03-25Human Genome Sciences, Inc.Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en)2001-05-252008-04-22Human Genome Sciences, Inc.Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
DE60235989D1 (en)2001-06-262010-05-27Amgen Fremont Inc ANTIBODIES AGAINST OPGL
US7572765B2 (en)2001-07-232009-08-11The General Hospital CorporationConformationally constrained parathyroid hormone (PTH) analogs
KR100453877B1 (en)2001-07-262004-10-20메덱스젠 주식회사METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
WO2004009775A2 (en)2002-07-192004-01-29Targacept, Inc.Methods and compositions relating to chimeric nicotinic receptor subunits
AU2003274011B2 (en)2002-10-152010-03-04Intercell AgNucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
AU2004206250B8 (en)2003-01-212009-09-17Bristol-Myers Squibb CompanyPolynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
DE602004022923D1 (en)2003-03-042009-10-15Intercell Ag STREPTOCOCCUS PYOGENES ANTIGENE
EP1610813A4 (en)2003-03-192009-07-01Gen Hospital Corp PARATHYROIDAL HORMONES CONFORMALLY CONFORMALLY CONSTRAINED WITH PROPELLER STABILIZERS $ G (A)
EP2311991A1 (en)2003-04-152011-04-20Intercell AGS. pneumoniae antigens
TWI353991B (en)2003-05-062011-12-11Syntonix Pharmaceuticals IncImmunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en)2003-05-062019-10-16Bioverativ Therapeutics Inc.Clotting factor-fc chimeric proteins to treat hemophilia
AU2012203896B2 (en)*2003-05-062014-09-25Bioverativ Therapeutics Inc.Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
EP2287177A3 (en)2003-05-072011-08-31Intercell AGStreptococcus agalactiae antigens I + II
EP1629005A2 (en)2003-05-302006-03-01Intercell AGEnterococcus antigens
EP1653985A4 (en)2003-07-172009-08-05Gen Hospital Corp CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES
CN103212084B (en)2003-11-132018-07-13韩美科学株式会社Contain pharmaceutical composition of the immunoglobulin FC region as carrier
US8110665B2 (en)2003-11-132012-02-07Hanmi Holdings Co., Ltd.Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
PT1740698E (en)2004-04-222010-11-02Talecris Biotherapeutics IncRecombinantly modified plasmin
EP1598428A1 (en)2004-05-182005-11-23Georg DewaldMethods and kits to detect Hereditary angioedema type III
WO2006012451A2 (en)2004-07-222006-02-02Five Prime Therapeutics, Inc.Compositions and methods of use for mgd-csf in disease treatment
WO2006027346A2 (en)2004-09-062006-03-16Altana Pharma AgNovel pyrazolopyrimidines
ES2342964T3 (en)*2004-12-092010-07-20Merck Patent Gmbh VARIATIONS OF INTERLEUCINE-7 WITH REDUCED IMMUNOGENICITY.
AU2006235266B2 (en)2005-04-072010-12-23The Cleveland Clinic FoundationGammaretrovirus associated with cancer
KR100754667B1 (en)2005-04-082007-09-03한미약품 주식회사 Immunoglobulin Fc Fragments Modified with Non-Peptide Polymers and Pharmaceutical Compositions Comprising the Same
AU2006280587B2 (en)2005-08-162011-02-24Hanmi Science Co., Ltd.A method for the mass production of immunoglobulin Fc region deleted initial methionine residues
EP3031470A3 (en)2005-09-092016-08-10The Johns Hopkins UniversityManipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
EP3037544A1 (en)2005-10-132016-06-29Human Genome Sciences, Inc.Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
JP5191392B2 (en)2005-11-072013-05-08ザ スクリプス リサーチ インスティチュート Compositions and methods for modulating the specificity of tissue factor signaling
EP1785434A1 (en)2005-11-112007-05-16Ludwig-Maximilians-Universität MünchenTargeting and tracing of antigens in living cells
EP3936621A1 (en)2006-01-202022-01-12Cell Signaling Technology, Inc.Translocation and mutant ros kinase in human non-small cell lung carcinoma
US7625564B2 (en)*2006-01-272009-12-01Novagen Holding CorporationRecombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
ES2391908T3 (en)2006-04-202012-11-30Becton,Dickinson And Company Thermostable proteins and procedures for obtaining and using them
US7572618B2 (en)2006-06-302009-08-11Bristol-Myers Squibb CompanyPolynucleotides encoding novel PCSK9 variants
WO2008019062A2 (en)2006-08-042008-02-14The General Hospital CorporationPolypeptide derivatives of parathyroid hormone (pth)
EP2275434A1 (en)2006-09-152011-01-19Intercell AGBorrelia antigens
US7833527B2 (en)2006-10-022010-11-16Amgen Inc.Methods of treating psoriasis using IL-17 Receptor A antibodies
KR100888022B1 (en)2006-12-212009-03-09재단법인 목암생명공학연구소 Fusion protein between immunoglobulin Fc and human apolipoprotein (a) kringle fragment L8 8Fc
WO2008122039A2 (en)2007-04-022008-10-09The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesSelenocysteine mediated hybrid antibody molecules
CA2685805A1 (en)2007-05-022008-11-13Intercell AgKlebsiella antigens
CN101883782A (en)2007-06-182010-11-10英特塞尔股份公司 Chlamydia antigen
BRPI0814465B1 (en)2007-07-262021-11-23Novagen Holding Corporation FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION
BRPI0814962B8 (en)2007-08-012021-05-25Chugai Pharmaceutical Co Ltd in vitro methods to determine whether a candidate compound is a long-acting or short-acting agonist of a g protein-coupled receptor, polypeptide, its use and pharmaceutical composition
JP4920084B2 (en)2007-09-272012-04-18株式会社ウイルス医科学研究所 Factors involved in latent infection of herpesvirus and their use
DK2203558T3 (en)2007-10-182016-06-27Cell Signaling Technology IncTRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
DK2242769T3 (en)2008-01-112017-02-06Adheron Therapeutics Inc ANTI-CADHERIN-11 EC1 DOMAIN ANTIBODIES FOR TREATMENT OF INFLAMMATORY LED DISEASES
AU2009234389B2 (en)2008-04-102014-08-21Cell Signaling Technology, Inc.Compositions and methods for detecting EGFR mutations in cancer
CA2726908C (en)2008-06-042017-01-24Talecris Biotherapeutics, Inc.Composition, method, and kit for preparing plasmin
NZ590358A (en)2008-07-232012-04-27Hanmi Holdings Co LtdA polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2881402B1 (en)2009-02-122017-05-10Cell Signaling Technology, Inc.Mutant ROS expression in human liver cancer
WO2010092176A2 (en)2009-02-132010-08-19Intercell AgNontypable haemophilus influenzae antigens
JP5789521B2 (en)2009-03-032015-10-07グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Compositions, methods and kits for producing plasminogen; and plasmin produced therefrom
TW201117824A (en)2009-10-122011-06-01Amgen IncUse of IL-17 receptor a antigen binding proteins
PL3295957T3 (en)2010-01-152020-03-31Kirin-Amgen, Inc.Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
US8883739B2 (en)2010-01-192014-11-11The Trustees Of Columbia University In The City Of New YorkOsteocalcin as a treatment for male reproductive disorders
CA2805267C (en)2010-05-042019-07-30The Brigham And Women's Hospital, Inc.Detection and treatment of fibrosis
EP2569003B1 (en)2010-05-132017-10-25The General Hospital CorporationParathyroid hormone analogs and uses thereof
AU2011279044B2 (en)2010-07-152013-12-19Adheron Therapeutics, Inc.Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
US20140234330A1 (en)2011-07-222014-08-21Amgen Inc.Il-17 receptor a is required for il-17c biology
EP2751258B1 (en)2011-09-022019-08-14Lifenet HealthBmp peptides & methods of use
US9290564B2 (en)2012-05-242016-03-22Mountgate Group LimitedCompositions and methods related to the prevention and treatment of rabies infection
EP2685260A1 (en)2012-07-092014-01-15Ludwig-Maximilians-Universität MünchenDirect and quantitative detection of targets in living cells
KR101609840B1 (en)*2012-07-122016-04-07한국생명공학연구원 Adsorption column for antibody purification using Fc region binding peptide of antibody
SMT201800163T1 (en)2012-09-112018-05-02Coherus Biosciences IncCorrectly folded etanercept in high purity and excellent yield
KR102073748B1 (en)2013-01-312020-02-05한미약품 주식회사Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
US10052364B2 (en)2013-03-152018-08-21The Trustees Of Columbia University In The City Of New YorkOsteocalcin as a treatment for cognitive disorders
AR096891A1 (en)2013-07-122016-02-03Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
AU2015241373B2 (en)2014-03-312020-11-05Amgen K-A, Inc.Methods of treating nail and scalp psoriasis
CA2960642A1 (en)2014-09-102016-03-17Georgetown UniversityCompositions and methods of using interleukin-4 induced gene 1 (il4i1)
EP3226889A4 (en)2014-11-192018-11-21The Trustees of Columbia University in the City of New YorkOsteocalcin as a treatment for frailty associated with aging
KR20240132521A (en)2015-03-132024-09-03삼성바이오에피스 주식회사Anti-tnf-alpha polypeptide composition and use thereof
AU2018364630A1 (en)2017-11-092020-05-21Pinteon Therapeutics Inc.Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
US12129298B2 (en)2018-06-212024-10-29Daiichi Sankyo Company, LimitedCompositions including CD3 antigen binding fragments and uses thereof
WO2020053808A1 (en)2018-09-122020-03-19Georg DewaldMethod of diagnosing vasoregulatory disorders
WO2020185763A1 (en)2019-03-112020-09-17Memorial Sloan Kettering Cancer CenterCd22 antibodies and methods of using the same
EP4277664A1 (en)2021-01-132023-11-22Memorial Sloan Kettering Cancer CenterAntibody-pyrrolobenzodiazepine derivative conjugate
JP2024503658A (en)2021-01-132024-01-26メモリアル スローン－ケタリング キャンサー センター Anti-DLL3 antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP0269455A3 (en)*1986-11-281989-09-06Takeda Chemical Industries, Ltd.Highly purified fused protein comprising human ige fc fragment and production thereof
ZA89430B (en)*1988-01-221989-10-25Gen Hospital CorpCloned genes encoding ig-cd4 fusion proteins and the use thereof
WO1991002743A1 (en)*1989-08-231991-03-07The General Hospital CorporationNon-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
US5395760A (en)*1989-09-051995-03-07Immunex CorporationDNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en)*1989-09-122006-11-23Ahp Mfg B V TFN-binding proteins
DK0574395T3 (en)*1990-11-092002-10-07Stephen D Gillies Cytokine immunoconjugates
EP0533006A1 (en)*1991-09-181993-03-24F.Hoffmann-La Roche & Co. AktiengesellschaftChimaeric interleukin 5-receptor/immunoglobulin polypeptides

Also Published As

Publication numberPublication date
DK0464533T3 (en)1999-04-26
CY2000009I1 (en)2016-10-05
ES2120949T3 (en)1998-11-16
NL300009I1 (en)2000-08-01
KR100249572B1 (en)2000-03-15
AU7935791A (en)1992-01-02
DE10075010I1 (en)2003-06-12
PT98113B (en)1998-12-31
PT98113A (en)1992-05-29
ATE309376T1 (en)2005-11-15
EP0835939B8 (en)2006-01-11
NL300009I2 (en)2000-12-01
IE912256A1 (en)1992-01-01
KR920000789A (en)1992-01-29
DE59109269D1 (en)2005-12-15
JPH05247094A (en)1993-09-24
HK1012015A1 (en)1999-07-23
EP0835939B1 (en)2005-11-09
ES2120949T4 (en)2011-12-29
AU655421B2 (en)1994-12-22
CY2151B1 (en)2002-08-23
HK1010216A1 (en)1999-06-17
GR3027567T3 (en)1998-11-30
DE59109032D1 (en)1998-09-03
EP0464533A1 (en)1992-01-08
KR100280070B1 (en)2001-01-15
EP0835939A3 (en)1998-04-22
UY25897A1 (en)2001-01-31
ATE169030T1 (en)1998-08-15
EP0464533B1 (en)1998-07-29
ES2251009T3 (en)2006-04-16
EP0835939A2 (en)1998-04-15
CA2045869C (en)2009-01-27
JP2002201200A (en)2002-07-16
EP1586635A1 (en)2005-10-19
CA2045869A1 (en)1991-12-29
KR100280069B1 (en)2001-01-15
JP3768427B2 (en)2006-04-19
DE10075010I2 (en)2004-01-29
LU90592I2 (en)2000-07-31

Similar Documents

PublicationPublication DateTitle
DK0835939T3 (en) Fusion proteins with proportions of immunoglobulin, their preparation and use
Thomas et al.Brain fibroblast growth factor: nonidentity with myelin basic protein fragments.
KR950032280A (en) Main active protein of rapamycin
DK1149905T3 (en) Methods and Preparation for Polypeptide Technology
BR0013231A (en) Multiple cytokine-antibody complexes
DE69228701D1 (en) Fragments of prion proteins.
DK1724354T3 (en) Circular DNA molecule with a dependent origin of replication, its method of preparation and its use in gene therapy
MY102472A (en)Preparation of funtional human urokinase proteins.
DK430486D0 (en) PROCEDURE FOR THE EXTRACTION OF PROTEIN
DE69534180D1 (en) PROMOTER OF TIE RECEPTOR PROTEIN KINASE
BR9709900A (en) Protein binding proteins of prions and their uses.
BR9713450A (en) Mammalian chemokines
DK0546087T3 (en) Protein structure of the plant toxin gelonin
ATE191568T1 (en) SPECIFIC BINDING SUBSTANCES FOR ANTIBODIES AND THEIR USE FOR IMMUNOASSAYS OR VACCINES
DK0941341T3 (en) Nucleotide sequence encoding a flavin monooxygenase, the corresponding protein and their applications in diagnostics and therapy
DE3855007D1 (en) METHOD FOR PURIFYING RECOMBINANT t-PA FROM THEIR CORRESPONDING HOST CELL PROTEINS
Ishaq et al.Purification and identification of antigenic polypeptides of Sm and RNP antigens of goat liver
Sikorski et al.Group fractionation of wheat germ ribosomal proteins
SE8800981D0 (en) A RECOMBINANT FUSION PROTEIN, ITS USE AND A RECOMBINANT VECTOR
ATE409746T1 (en) NEW VOLTAGE DEPENDENT POTASSIUM CHANNEL AND ITS USE FOR DEVELOPING THERAPEUTICS
Alcaraz et al.Tryptic and plasmic cleavage of a rat myeloma IgD
DE69836226D1 (en) IFN RECEPTOR 1 BINDING PROTEINS, DNA PROCESSING THEREFOR AND METHOD FOR REGULATING THE CELLULAR ANSWER TO INTERFERONE
Mannhalter4. Therapy with Plasminogen Concentrates: Preliminary Results and Future Strategies
IT8421612A0 (en) CLONING VECTOR, PROCEDURE FOR ITS CONSTRUCTION AND PROCEDURE FOR CONCENTRATION AND PURIFICATION OF PRODUCED PROTEINS, FORMED BY THE CLONING VECTOR.
FI934079L (en) Method for preparing a fusion protein
[8]ページ先頭
©2009-2025 Movatter.jp